{"title":"肺立体定向放射治疗外周非小细胞肺癌的同时综合bed升级。","authors":"Colton J Ladbury, Sagus Sampath","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Report the outcomes of patients with non-small cell lung cancer (NSCLC) and peripheral tumors treated with simultaneous integrated biologically equivalent dose (BED)-escalation (SIBE) lung stereotactic body radiation therapy (SBRT) to achieve dose escalation.</p><p><strong>Materials/methods: </strong>Patients with NSCLC within 5 mm of the chest wall treated with a SIBE approach were eligible. Patients received 60 Gy in 5 fractions, with dose decreased to 50 Gy based on proximity to the chest wall. Dosimetry, oncologic outcomes, and toxicity were evaluated.</p><p><strong>Results: </strong>Twenty-four patients met inclusion criteria. Median BED to the PTV was 135.4 Gy. Median chest wall V30 was 18.7 cc. The 3-year LC, OS, and PFS of the non-metastatic cohort was 93%, 35%, and 39%, respectively. The crude rate of chest wall toxicity was 12.5%, with no rib fractures.</p><p><strong>Conclusions: </strong>SIBE lung SBRT appears to be well tolerated and achieves favorable local control rates and survival.</p>","PeriodicalId":16917,"journal":{"name":"Journal of radiosurgery and SBRT","volume":"8 3","pages":"181-187"},"PeriodicalIF":0.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970741/pdf/rsbrt-8-181.pdf","citationCount":"0","resultStr":"{\"title\":\"Lung stereotactic body radiation therapy using simultaneous integrated BED-escalation for peripherally located non-small cell lung cancer.\",\"authors\":\"Colton J Ladbury, Sagus Sampath\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Report the outcomes of patients with non-small cell lung cancer (NSCLC) and peripheral tumors treated with simultaneous integrated biologically equivalent dose (BED)-escalation (SIBE) lung stereotactic body radiation therapy (SBRT) to achieve dose escalation.</p><p><strong>Materials/methods: </strong>Patients with NSCLC within 5 mm of the chest wall treated with a SIBE approach were eligible. Patients received 60 Gy in 5 fractions, with dose decreased to 50 Gy based on proximity to the chest wall. Dosimetry, oncologic outcomes, and toxicity were evaluated.</p><p><strong>Results: </strong>Twenty-four patients met inclusion criteria. Median BED to the PTV was 135.4 Gy. Median chest wall V30 was 18.7 cc. The 3-year LC, OS, and PFS of the non-metastatic cohort was 93%, 35%, and 39%, respectively. The crude rate of chest wall toxicity was 12.5%, with no rib fractures.</p><p><strong>Conclusions: </strong>SIBE lung SBRT appears to be well tolerated and achieves favorable local control rates and survival.</p>\",\"PeriodicalId\":16917,\"journal\":{\"name\":\"Journal of radiosurgery and SBRT\",\"volume\":\"8 3\",\"pages\":\"181-187\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970741/pdf/rsbrt-8-181.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of radiosurgery and SBRT\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of radiosurgery and SBRT","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
Lung stereotactic body radiation therapy using simultaneous integrated BED-escalation for peripherally located non-small cell lung cancer.
Purpose: Report the outcomes of patients with non-small cell lung cancer (NSCLC) and peripheral tumors treated with simultaneous integrated biologically equivalent dose (BED)-escalation (SIBE) lung stereotactic body radiation therapy (SBRT) to achieve dose escalation.
Materials/methods: Patients with NSCLC within 5 mm of the chest wall treated with a SIBE approach were eligible. Patients received 60 Gy in 5 fractions, with dose decreased to 50 Gy based on proximity to the chest wall. Dosimetry, oncologic outcomes, and toxicity were evaluated.
Results: Twenty-four patients met inclusion criteria. Median BED to the PTV was 135.4 Gy. Median chest wall V30 was 18.7 cc. The 3-year LC, OS, and PFS of the non-metastatic cohort was 93%, 35%, and 39%, respectively. The crude rate of chest wall toxicity was 12.5%, with no rib fractures.
Conclusions: SIBE lung SBRT appears to be well tolerated and achieves favorable local control rates and survival.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
